Abstracts tagged "Pediatric rheumatology"

Abstract Number: L22 • 2019 ACR/ARP Annual Meeting
Tofacitinib for the Treatment of Polyarticular Course Juvenile Idiopathic Arthritis: Results of a Phase 3 Randomized, Double-blind, Placebo-controlled Withdrawal Study
Hermine Brunner¹, Olga Synoverska ², Tracy Ting ³, Carlos Abud Mendoza ², Alberto Spindler ², Yulia Vyzhga ², Katherine Marzan ³, Vladimir Keltsev ², Irit Tirosh ², Lisa Imundo ³, Rita Jerath ³, Daniel Kingsbury ³, Betul Sozeri ², Sheetal Vora ³, Sampath Prahalad ³, Elena Zholobova ², Yonatan Butbul Aviel ², Vyacheslav Chasnyk ², Melissa Lerman ³, Kabita Nanda ³, Heinrike Schmeling ³, Heather Tory ³, Yosef Uziel ², Diego Oscar Viola ², Holly Posner ⁴, Keith Kanik ⁵, Ann Wouters ⁴, Cheng Chang ⁵, Richard Zhang ⁴, Irina Lazariciu ⁶, Ming-Ann Hsu ⁵, Ricardo Suehiro ⁷, Alberto Martini ², Daniel J. Lovell ³ and Nicolino Ruperto ⁸, ¹PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, ²PRINTO, Istituto Giannina Gaslini, Genova, Italy, ³PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, ⁴Pfizer Inc, New York, New York, ⁵Pfizer Inc, Groton, Connecticut, ⁶IQVIA, Montreal, Quebec, Canada, ⁷Pfizer Inc, Collegeville, Pennsylvania, ⁸PRINTO, Istituto Giannina Gaslini, Genoa, Italy
Background/Purpose: Tofacitinib is an oral JAK inhibitor that is being investigated for JIA. Here we assess the efficacy and safety of tofacitinib in patients (pts)…
Abstract Number: 1748 • 2019 ACR/ARP Annual Meeting
Incidence of Retinopathy in Individuals Who Initiated Hydroxychloroquine Therapy During Childhood
Sara Patrizi¹, Douglas Stram ², Miranda Weintraub ³ and Alexandra Aminoff ¹, ¹Kaiser Permanente, Department of Pediatrics, Oakland, ²Kaiser Permanente Northern California, Division of Research, Oakland, ³Kaiser Permanente, Department of Graduate Medical Education, Oakland
Background/Purpose: Hydroxychloroquine (HCQ), a medication used to treat Systemic Lupus Erythematosus (SLE), Discoid Lupus Erythematosus (DLE) and Sjogren’s Syndrome (SS), reduces disease flare-ups, organ damage,…
Abstract Number: 2727 • 2019 ACR/ARP Annual Meeting
Mitochondrial Contribution to Juvenile Dermatomyositis Pathogenesis
Bhargavi Duvvuri¹, Lauren Pachman ², Richard Moore ¹, Gabrielle Morgan ², Marisa Klein-Gitelman ², Megan L. Curran ³, Stephen Doty ⁴ and Christian Lood ¹, ¹University of Washington, Seattle, ²Northwestern University, Chicago, ³University of Colorado, Aurora, CO, ⁴Hospital for Special Surgery, New York
Background/Purpose: Though mainly found intracellularly, we recently observed mitochondrial extrusion upon cell death, contributing to inflammation and organ damage in lupus-prone mice. Of note, mitochondria…
Abstract Number: 1751 • 2019 ACR/ARP Annual Meeting
A Systematic Literature Review of Efficacy and Safety of Biologic Agents for the Treatment of Juvenile Dermatomyositis
edoardo marrani¹, Sarah Abu Rumeileh ¹, Francesca Tirelli ², Ilaria Maccora ³ and Gabriele Simonini ⁴, ¹Post graduate School of pediatrics, University of Florence, Firenze, Italy, ²Post Graduate School of Pediatrics, University of Florence, Florence, Italy, Firenze, Italy, ³Post Graduate School of Pediatrics, University of Florence, Florence, Italy, Florence, Toscana, Italy, ⁴Anna Meyer Children's Hospital, Flotence, Italy
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare, chronic autoimmune illness characterized by symmetric, proximal muscle damages and involvement of the skin. While first line treatment…
Abstract Number: 2864 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Intravenous Belimumab in Children with Systemic Lupus Erythematosus: An Across-Trial Comparison with the Adult Belimumab Studies
Antonio Nino¹, Damon L Bass ², Gina Eriksson ¹, Anne Hammer ¹, Beulah Ji ³, Holly Quasny ⁴ and David Roth ⁵, ¹GlaxoSmithKline, Collegeville, ²GlaxoSmithKline, Collegeville, PA, ³GSK, Uxbridge, Middlesex, United Kingdom, ⁴GlaxoSmithKline, Research Triangle Park, ⁵GSK, Collegeville, PA
Background/Purpose: Belimumab (BEL) is the first treatment approved for children with systemic lupus erythematosus (SLE) from 5 years of age and older.1 This approval was…
Abstract Number: 1753 • 2019 ACR/ARP Annual Meeting
Are Patterns of Early Disease Severity Predictive of Grade 12 Academic Achievement in Patients with Childhood-onset Chronic Rheumatic Diseases?
Lily SH Lim¹, Okechukwu Ekuma ², Ruth Ann Marrie ¹, Marni Brownell ², Christine Peschken ¹, Carol Hitchon ¹, Kerstin Gerhold ¹ and Lisa Lix ³, ¹University of Manitoba, Winnipeg, MB, Canada, ²Manitoba Center for Health Policy, Winnipeg, MB, Canada, ³University of Manitoba, Winnipeg, Canada
Background/Purpose: Youths with childhood-onset chronic rheumatic diseases (ChildCRD), including juvenile arthritis (JA) and systemic autoimmune rheumatic diseases (SARD), have worse grade 12 standards tests results…
Abstract Number: 2867 • 2019 ACR/ARP Annual Meeting
Nocturnal Blood Pressure Dipping as a Marker of Endothelial and Cardiac Function in Pediatric-onset Systemic Lupus Erythematosus
Joyce Chang¹, Taylor Goldberg ¹, Sarah McGuire ¹, Lindsay Waqar ¹, Kevin Meyers ¹, Laura Mercer-Rosa ¹, Pamela F. Weiss ¹ and Andrea Knight ², ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: There is a need for clinically useful measures of cardiovascular (CV) risk in pediatric-onset SLE (pSLE). Nocturnal blood pressure (BP) non-dipping (loss of the…
Abstract Number: 1756 • 2019 ACR/ARP Annual Meeting
Health-related Social Media Use by Parents of Children with Rheumatic Diseases
Jonathan Hausmann¹, Vincent Del Gaizo ², Kara Magane ³, Alexandra Marin ⁴, Shannon Malloy ⁵, Sanjay Mishra ⁶, Tory Aquino ⁷, Marc Natter ⁸, Laura Schanberg ⁹ and Elissa Weitzman ⁸, ¹Boston Children's Hospital / Beth Israel Deaconess Medical Center, Boston, MA, ²Childhood Arthritis and Rheumatology Research Alliance, Whitehouse Station, NJ, ³Boston Children’s Hospital, Boston, MA, ⁴Boston Children's Hospital, Boston, MA, ⁵Cure JM Foundation, Seattle, WA, ⁶Seattle Public Schools, Seattle, WA, ⁷Hearing Life, Patterson Heights, PA, ⁸Boston Children’s Hospital / Harvard Medical School, Boston, MA, ⁹Duke University Medical Center, Durham, NC
Background/Purpose: Disease and treatment burdens are high for children living with rheumatic diseases. Pediatric patients and their families lack a mature evidence base to guide…
Abstract Number: 170 • 2019 ACR/ARP Annual Meeting
Evaluating an Illustrated Storybook for Children with Juvenile Idiopathic Arthritis
Jimin Lee¹, Dennis Newhook ², Kaylee Eady ² and Roman Jurencak ¹, ¹Children's Hospital of Eastern Ontario, Ottawa, ON, Canada, ²CHEO Research Institute, Ottawa, ON, Canada
Background/Purpose: While juvenile idiopathic arthritis (JIA) is a common pediatric rheumatic disease, there is a lack of available child-friendly patient education materials. An illustrated storybook…
Abstract Number: 1757 • 2019 ACR/ARP Annual Meeting
Review of Effectiveness of an Intensive Rehabilitation Programme in Managing Strength, Pain and Function in 123 Young People with Rheumatological Conditions
Susan Maillard¹, Kim Noar ² and Lauren Stone ², ¹Great Ormond Street Hospital NHS Foundation Trust, Maidenhead, United Kingdom, ²Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom
Background/Purpose: Young people with Rheumatological conditions often experience ongoing pain, muscle weakness and reduced function despite modern medication. The unit at Great Ormond Street Hospital…
Abstract Number: 776 • 2019 ACR/ARP Annual Meeting
Genetic Signatures Support Inflammation Driven Fibrosis in Localized Scleroderma
Christina Schutt¹, Emily Mirizio ², Claudia Salgado ³, Miguel Reyes-Mugica ³, Kaila L. Schollaert ² and Kathryn Torok ³, ¹UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, ³UPMC Children's Hospital of Pittsburgh, Pittsburgh
Background/Purpose: Localized scleroderma (LS) is a progressive autoimmune disease of the skin and underlying tissue that is characterized by an initial inflammatory infiltration which is…
Abstract Number: 1813 • 2019 ACR/ARP Annual Meeting
New Medications Are Needed for Children with Juvenile Idiopathic Arthritis
Hermine Brunner¹, Laura Schanberg ², Yukiko Kimura ³, Anne Dennos ⁴, Guy Eakin ⁵, Dominic Co ⁶, Robert Colbert ⁷, Robert Fuhlbrigge ⁸, Ellen Goldmuntz ⁹, Daniel Kingsbury ¹⁰, Sandra Mintz ¹¹, Karen Onel ¹², Cathy Patty-Resk ¹³, Lisa G. Rider ¹⁴, Rayfel Schneider ¹⁵, Allen Watts ¹⁶, Emily von-Scheven ¹⁷, Daniel J. Lovell ¹⁸, Timothy Beukelman ¹⁹ and for PRCSG Advisory Council and CARRA Registry Investigators ²⁰, ¹Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Duke University Medical Center, Durham, NC, ³Joseph M Sanzari Children's Hospital, Hackensack University Medical Center, Cincinnati, OH, ⁴Duke Clinical Research Institute, Durham, NC, ⁵Arthritis Foundation, Atlanta, ⁶of Wisconsin School of Medicine and Public Health, Madison, WI, ⁷Pediatric Clinical Trials Unit, Pediatric Translational Research Branch, NIAMS, NIH, Bethesda, MD, ⁸Department of Rheumatology, Children’s Hospital Colorado, Denver, CO, ⁹NIAID, Washingto, DC, ¹⁰LHS Pediatrics, Prtland, OR, ¹¹Children's Hospital of Los Angeles, Los Angeles, CA, ¹²Hospital for Special Surgery, Division of Pediatric Rheumatology, New York, NY, ¹³Children's Hospital of Michigan, Detroit, MI, ¹⁴Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Bethesda, MD, ¹⁵Hospital for Sick Children, Toronto, ON, Canada, ¹⁶Cincinnati Children's Hospital MEdical Center, Cincinnati, OH, ¹⁷University of California San Francisco, San Francisco, ¹⁸Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, ¹⁹University of Alabama Birmingham, Birmingham, AL, ²⁰Pediatric Rheumatology Collaborative Study Group, Cincinnati, OH
Background/Purpose: Existing legislation in the United States (US) promotes the study of new medications in children. Biologic disease-modifying-drugs (bDMARDs) and small molecules proven effective and…
Abstract Number: 786 • 2019 ACR/ARP Annual Meeting
Distinguishing S100 Proteins and Cytokine Levels Between Active and Inactive Uveitis in Children with Juvenile Idiopathic Arthritis
Jackeline Rodriguez-Smith¹, Virginia Utz ², Sherry Thornton ¹, Grant Schulert ¹, Adam Kauffman ³, Alyssa Sproles ¹, Najima Mwase ¹, Theresa Hennard ⁴, Alexei A. Grom ¹, Mekibib Altaye ⁵, Gary Holland ⁶ and Sheila Angeles-Han ⁷, ¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Division of Ophthalmology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Cincinnati Eye Institute and Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Division of Rheumatology, Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ⁵Divison of Biostatistics and Epidemiology and Department of Pediatrics, University of Cincinnati, Cincinnati, OH, ⁶UCLA Stein Eye Institute and David Geffen School of Medicine at University of California, Los Angeles, Ca, Los Angeles, CA, ⁷Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cinicinnati
Background/Purpose: Uveitis occurs in 10-20% of children with Juvenile Idiopathic Arthritis (JIA) and is typically asymptomatic. Ocular complications occur in 50% of children, (i.e. cataracts,…
Abstract Number: 1920 • 2019 ACR/ARP Annual Meeting
School Nurse Education for Juvenile Idiopathic Arthritis
W. Blaine Lapin¹, Carleigh Kutac ², Danielle Guttman-Lapin ³, Amanda Brown ², Eyal Muscal ² and Filiz Seeborg ², ¹Baylor College of Medicine, Connecticut Children's Medical Center, Houston, TX, ²Baylor College of Medicine, Houston, TX, ³Aldine Independent School District, Houston, TX
Background/Purpose: There is a paucity of literature on the challenges children with JIA face at school. Despite treatment advances, children with JIA often rate their…
Abstract Number: 797 • 2019 ACR/ARP Annual Meeting
Characteristics of Coexisting Localized Scleroderma and Juvenile Idiopathic Arthritis
Daniel Reiff¹, Courtney Crayne ², Melissa Mannion ³ and Randy Cron ¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, ³University of Alabama at Birmingham, Alabama
Background/Purpose: Localized scleroderma (LS), including morphea and linear scleroderma, is an autoimmune disease where excessive collagen deposits underneath the skin lead to thickening, scarring, and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].